Prof Hang Quach
Honorary Clinical Professor
Department of Medicine
555 Scholarly works
3 Projects
HIGHLIGHTS
2026
Journal article
Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO
DOI: 10.1038/s41408-025-01436-02026
Journal article
Characterising Diagnostic Delay in Cardiac Amyloidosis: An Exploratory Study of Factors Impacting Time to Diagnosis
DOI: 10.1016/j.hlc.2026.07.2742026
Journal article
Translocation t(11;14) and BCL2-inhibition in multiple myeloma
DOI: 10.3324/haematol.2025.2891472026
Journal article
Prevalence of Abnormal Free Light Chain Assessment in ATTR Amyloidosis and Impact of Reclassification With the revised iSTOPMM Criteria for Light-Chain Monoclonal Gammopathy
DOI: 10.1016/j.hlc.2026.07.3432026
Journal article
Estimating the Burden of ATTR Cardiac Amyloidosis in Australia: Modelling Used Reported Rates and Real-World Data
DOI: 10.1016/j.hlc.2026.07.2982026
Journal article
Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry
DOI: 10.1111/bjh.706092018
Research grants (other domestic)
Novel Immunotherapy Approach for Rescuing Inadequate Responses and Resistance to Treatment for Patients With Multiple Myeloma
RECENT SCHOLARLY WORKS
2026
Journal article
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
DOI: 10.1056/NEJMoa26038702026
Journal article
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial
DOI: 10.1016/S0140-6736(26)01088-32026
Journal article
Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE
DOI: 10.1182/bloodadvances.20250193232026
Journal article
Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial.
DOI: 10.1200/jco.2026.44.17_suppl.lba7506
RECENT PROJECTS
2013
Research Grant
Targeting GRP-78 as a Means to Overcome Drug Resistance and as a Therapeutic Modaliaty Against Multiple Myeloma
2014
Research Grant
Targeting GRP-78 as a Means to Overcome Drug Resistance and as a Therapeutic Modaliaty Against Multiple Myeloma